Cohance Lifesciences Ltd
COHANCECohance Lifesciences Ltd's three tracks disagree. Price, valuation and the earnings engine each tell a different story — the next quarter or two settles it.
The sharpest disagreement: Promoters moved +7.4 points over 8 quarters while the operating story went the other way — someone close to the numbers is not convinced.
The price is in a downtrend (56 weeks in) while the P/E sits at the 86th percentile of its own 6-year range. Underneath, the last four quarters read deteriorating — profit −92.9% year on year, and 142% of the last 3 years' profit arrived as cash. What settles it: whether the register turns back in the story’s favour.
Price story Before the numbers, the tape. A stock price moves through four repeating seasons: a flat base (stage 1), an advance (2), a top (3), a decline (4). Where the price sits in that cycle frames everything below.
Cohance Lifesciences Ltd trades at ₹442, in a downtrend and 56 weeks into that stage. That is −15.1% against its own 200-day average. It sits at 23% of a 52-week range of ₹280 to ₹980. On relative strength it has been ahead of the NIFTY 500 on a trailing-13-week view for 2 straight weeks.
Today the stock is in a downtrend — week 56 of stage 4, confirmed. At ₹442 it trades −15.1% versus its 200-day average and sits at 23% of its 52-week range (₹280–₹980).
Against the market, two honest reads. Cumulative: over the last 6.3 years the stock moved +203% while the NIFTY 500 moved +233% — behind the index over the full window. Recent form: on a trailing-13-week view the stock has been ahead for 2 straight weeks — the ribbon below is that same metric, week by week.
What would end the trend, mechanically: two Friday closes in a row below the 200-day line. That is the exit rule — no debates.
→ The trend is one thing; the bill is another. Are you paying up for it? Next: the P/E sits at the 86th percentile of its own range.
Valuation P/E is the price of ₹1 of annual profit: how many rupees the market pays for each rupee the company earns in a year.
Cohance Lifesciences Ltd trades at 80.9× P/E, at the pricey end of its own range (86th percentile). Its long-run median P/E is 35.4×, measured across 6.1 years of weekly readings. This places the multiple against the stock’s own record, and says nothing about what the business is worth.
Today's P/E of 80.9× is at the pricey end of its own range (86th percentile), against a long-run median of 35.4× measured over 6.1 years of weekly readings. This is a comparison against the stock's own history — not a claim about what it is worth.
Why the multiple sits where it does: over the past year annual EPS moved −55.5% against a −59.2% price move — earnings outran the price, pushing the multiple DOWN its own range.
The price move, decomposed: over 5y, of the −1.0%/yr price move, ~−18.4%/yr came from earnings growth and ~+17.4 pp from the multiple (expanding). The split is the honest approximate (price return minus earnings growth); it makes the rally itself visible instead of hiding it behind the percentile.
Put together: the multiple is full against its own past, so the story rests on the earnings line underneath it, not the multiple.
The PEG ratio and its quarterly curve, which only the second data source carries, are not drawn on this page: its two data sources disagree by up to 129% on reported income across 14 comparable periods. A figure two sources cannot agree on is not drawn — the gap is a decision, not missing data.
→ Cheap or dear rides on the earnings. Are they actually growing? Next: the fundamental stage — where the business sits in its arc, and how growth has compounded.
Stage: Deteriorating Every business sits somewhere on a fundamental arc, and this page names the spot before anything else. The last twelve quarters of revenue, profit and EPS growth — plus the return the business earns on its capital — are read as curves: Deteriorating (the curves are falling), Turning around (a trough has just formed and the last few quarters lift off it), Improving (the climb off the trough is sustained), Consistent (steadily positive with healthy returns), Topping out (still high but decelerating from the peak). When the curves genuinely disagree the read is Mixed; too little history is No read. CAGR (compound annual growth rate) is the smooth yearly pace that turns the starting value into the latest one — the fairest way to compare growth across different time spans. Read the columns together: if the 1-year number towers over the 10-year, recent growth is running hotter than the long-run trend. A dash means that window is not held, or the base year was a loss (where a growth rate is not meaningful).
Cohance Lifesciences Ltd reads as deteriorating on its fundamental arc. Deteriorating — revenue and profit growth are shrinking (revenue growth −26.3% latest (single-quarter readings) against +100.0% at its 12-quarter best), ROCE slipping at 8.0%. The read is built from 10 quarters across 3 curves, on partial evidence.
🚨 Why it matters: falling curves mean every cheap-looking ratio below needs a discount for direction.
One or more growth curves carry a base-effect spike — a large year-on-year move off a near-zero or loss-making comparable quarter. Those spikes are capped before the classifier reads the trajectory, and shown pinned on the chart, so a single distorted quarter does not drive the stage call.
Return readings here are annual, not quarterly — read as level and direction only; they can confirm the growth curves but never drive the stage on their own.
A partial read: at least one curve is short, or the returns curve is not the computed quarterly series — hold the stage word a little more loosely.
| 1yr | 3yr | 5yr | 10yr | |
|---|---|---|---|---|
| Revenue | +89.4% | +19.2% | +17.6% | — |
| Profit | −43.4% | −28.5% | −16.2% | — |
| EPS | −55.5% | −33.8% | −19.9% | — |
| Share price | −59.2% | −3.2% | −1.0% | — |
→ The stage names the trajectory. Next: the revenue line that produces it, quarter by quarter.
4-Factor Sector Score
28.0/100 — rank 22 of 24 in Pharma - API & CRAMS · 73% evidence confidence
Cohance Lifesciences Ltd scores 28.0 out of 100 against the 24 companies it is compared with in Pharma - API & CRAMS, ranking 22. Balanced evidence: keep at normal research priority and require another comparable period before raising conviction.
The four contributions add to the total exactly: 6.3 + 11.5 + 7.1 + 3.1 = 28. This is the SAME number shown on the sector comparison — it is computed once, for the whole peer set, and read here.
What would change it: The read weakens if profit growth turns negative or margin improvement reverses while sector-relative strength deteriorates.
Revenue Revenue is the top line: everything the company billed its customers in the period.
Cohance Lifesciences Ltd reported ₹619 Cr of revenue in the Mar 26 quarter, −26.3% year on year. Over 7 years it has compounded at 29.2% a year. The last full year, FY26, came in at ₹2,269 Cr. The last four reported quarters add to ₹2,269 Cr.
Cohance Lifesciences Ltd reported ₹619 Cr of revenue in the Mar 26 quarter, −26.3% year on year. Over 7 years it has compounded at 29.2% a year. The last full year, FY26, came in at ₹2,269 Cr. The last four reported quarters add to ₹2,269 Cr.
FY26 revenue came in at ₹2,269 Cr (+89.4% on the year), capping 7 years at 29.2% compound. The latest quarter (Mar 26) printed ₹619 Cr, −26.3% year on year.
Pace check: the last four quarters averaged −10.3% growth against the decade's 29.2% — the current year is running slower than its own long-run rate.
Acceleration check: trailing-twelve-month revenue grew −13.0% over the last 4 quarters against +46.9%/yr over the last 8 — rolling over; TTM profit −69.0% vs −29.3%/yr — rolling over.
→ Revenue slipped — did margins hold as it scaled? Next: 15.9% this quarter (−11.3 pp YoY).
Operating margin Operating margin is what is left of every ₹100 of sales after running the business, before interest and tax. It is the cleanest read on pricing power and cost control.
Cohance Lifesciences Ltd's operating margin is 15.9% in the Mar 26 quarter, −11.3 percentage points against the same quarter a year ago. Across 8 fiscal years the operating margin has ranged 19.0% to 46.0%. The current quarter is running below every full year in that window.
Cohance Lifesciences Ltd's operating margin is 15.9% in the Mar 26 quarter, −11.3 percentage points against the same quarter a year ago. Across 8 fiscal years the operating margin has ranged 19.0% to 46.0%. The current quarter is running below every full year in that window.
The latest quarter's operating margin is 15.9%, −11.3 pp against the same quarter a year ago. Across 8 fiscal years the operating margin has ranged 19.0%–46.0%.
🚨 Why the margin moved: operating margin went −11.3 pp year on year while gross margin went +1.1 pp — the loss came mostly below the gross line: operating leverage, with costs spread over a bigger revenue base.
→ Margins slipped — did that reach the bottom line? Next: profit −92.9% in the latest quarter.
Net profit Net profit is what survives every cost, interest and tax — the number EPS, dividends and book value all grow from.
Cohance Lifesciences Ltd earned ₹8.3 Cr of net profit in the Mar 26 quarter, −92.9% year on year. Full-year FY26 profit was ₹150 Cr. The 7-year compound rate is 4.7%. That is 1.3% of the quarter's revenue. The same quarter a year earlier earned ₹117 Cr.
Cohance Lifesciences Ltd earned ₹8.3 Cr of net profit in the Mar 26 quarter, −92.9% year on year. Full-year FY26 profit was ₹150 Cr. The 7-year compound rate is 4.7%. That is 1.3% of the quarter's revenue. The same quarter a year earlier earned ₹117 Cr.
Mar 26 profit was ₹8.3 Cr, −92.9% year on year. On the full year, FY26 printed ₹150 Cr (−43.4%), and the 7-year compound rate is 4.7%.
🚨 Why profit moved: revenue contributed −26.3% and the margin −11.3 pp — the quarter was revenue-led despite a thinner margin.
Pace comparison, last four quarters: profit −66.1% vs revenue −10.3%. Profit is growing slower than sales — costs are eating the growth before it reaches the bottom line.
→ Profit rose — but did the cash follow? Next: 142% of the last 3 years' profit arrived as cash.
Cash flow — the router The P&L says what was earned; the cash-flow statement says what actually arrived. Operating cash flow (CFO) against profit is the cleanest lie detector in the accounts.
Over the last 3 fiscal years 142% of Cohance Lifesciences Ltd's reported profit arrived as operating cash — the cash follows the profit. In FY26 that was ₹368 Cr of operating cash against ₹150 Cr of profit. After ₹1,764 Cr of capital spending, ₹−1,396 Cr was left as free cash.
FY26: operating cash of ₹368 Cr against reported profit of ₹150 Cr, leaving free cash of ₹−1,396 Cr after ₹1,764 Cr of capital spending. Across the last 3 fiscal years the conversion rate is 142% of profit.
Cash-flow readings here are annual — that is the resolution our series carries, so this section moves once a year.
Why conversion sits at 142%: the cash cycle stretched 83 days between FY21 and FY26 — more of each rupee of profit waits inside the cycle before arriving.
Router verdict: the bigger cash user is investment — capital spending ran 9.5× depreciation over three years, so the next section's job is to check what that build-out is buying.
→ So follow the cash to where it goes. Next: ₹3,037 Cr of building over 3 years.
Where the cash goes Working capital is the cash tied up between paying suppliers and getting paid: debtor days (customers owe), inventory days (stock waits), and the cash conversion cycle (the whole loop, in days of sales).
Cohance Lifesciences Ltd's cash conversion cycle runs 263 days in FY26, up from 180 days in FY21. Capital spending ran ₹3,037 Cr over the last 3 years. At FY26 sales of ₹2,269 Cr each day of that cycle holds about ₹6.2 Cr, so roughly ₹1,635 Cr sits inside the business at any moment.
FY26: debtors at 110 days, inventory at 310 days — roughly 10.2 months of stock waiting to sell; that is where the cash sits while it waits — for a full cycle of 263 days, looser than FY21's 180.
The full loop: cash goes out to suppliers and production on day 0; stock waits 310 days to sell; customers pay about 110 days after that; and suppliers themselves are paid at 157 days — netting out to the 263-day cycle.
In money terms: at FY26 sales of ₹2,269 Cr, each day of the cycle holds about ₹6.2 Cr — so the 263-day loop keeps roughly ₹1,635 Cr sitting inside the business at any moment.
On the investment side: capital spending of ₹3,037 Cr over the last 3 fiscal years against ₹319 Cr of depreciation — the company is building well ahead of wear-and-tear. Capital work-in-progress stands at ₹173 Cr (FY26) — capacity paid for but not yet earning.
The synthesis: the cash is going into capacity, not disappearing into the cycle — the question becomes whether the new capacity earns.
→ Does all this activity actually earn its cost of capital? Next: ROCE is 8%.
Return on capital Return on capital employed (ROCE) is the profit the whole business earns on all the money in it — equity and debt together. It is the single best test of whether growth creates value or just size.
Cohance Lifesciences Ltd earns a ROCE of 8% in FY26. A return-on-invested-capital spread against the cost of capital is not computable from what is held here. The wiring behind it is 6.6% net margin on 0.40× asset turns.
FY26 ROCE is 8%.
Why the return is what it is — the wiring (FY26): 6.6% net margin × 0.40× asset turns × 1.47× balance-sheet leverage ≈ 3.9% on equity. Margin does its share; leverage is modest — this is an earned return, not a borrowed one.
The quarterly return curves and the return-on-invested-capital overlay, which only the second data source carries, are not drawn on this page: its two data sources disagree by up to 129% on reported income across 14 comparable periods. A figure two sources cannot agree on is not drawn — the gap is a decision, not missing data.
→ Returns like these — is the balance sheet borrowing to make them? Next: debt-to-equity is 0.10.
Debt Debt-to-equity says how much of the business is funded by borrowings; interest cover says how many times operating profit pays the interest bill. Low and high, respectively, is the safe corner.
Cohance Lifesciences Ltd carries ₹400 Cr of borrowings against ₹3,911 Cr of equity in FY26, a debt-to-equity of 0.10. Operating profit covers the interest bill 12×. Over 5 years borrowings went from ₹143 Cr to ₹400 Cr. Capital spending ran ₹3,037 Cr across the last 3 of those years.
FY26: borrowings of ₹400 Cr against equity of ₹3,911 Cr — a debt-to-equity of 0.10. Operating profit covers the interest bill 12×. Over 5 years borrowings went from ₹143 Cr to ₹400 Cr while capital spending ran ₹3,037 Cr in just the last 3 — part of the build-out is riding on borrowed money.
The total-debt and debt-to-equity series, which only the second data source carries, are not drawn on this page: its two data sources disagree by up to 129% on reported income across 14 comparable periods. A figure two sources cannot agree on is not drawn — the gap is a decision, not missing data.
→ Who owns this, and are they adding or leaving? Next: Promoters added 7.4 points over 8 quarters.
Ownership Who owns the stock, quarter by quarter: promoters (the controlling owners), foreign and domestic institutions, and the public. Steady accumulation by people close to the numbers is a signal; a quiet register is also an answer.
Promoters added 7.4 points of Cohance Lifesciences Ltd over 8 quarters, the biggest move on the register. That takes promoters to 57.5% of the company. Foreign institutions moved −3.3 points over the same window, to 6.5%. The register is read on the four disclosed classes only; nothing is inferred between filings.
The register over the last two years — Promoters: +7.4 points over 8 quarters to 57.5%; Foreign institutions: −3.3 points over 8 quarters to 6.5%; Domestic institutions: +2.7 points over 8 quarters to 20.1%.
Why the register moved: rotation — foreign institutions −3.3 points against domestic institutions +2.7 points over 8 quarters, with promoters +7.4 points — one class of institutions handing the register to the other, not a verdict change by the people closest to the numbers.
→ One last check: does the safety math agree? Next: the balance-sheet safety line.
Safety line The Z-score estimates how far a company sits from balance-sheet distress — above roughly 3 is safe, below roughly 1.8 is the danger zone. It was built for manufacturers, so it is not applied to banks and lenders.
Cohance Lifesciences Ltd: the Z-score is not available for this stock, so we say so rather than invent one. It is a distance-to-distress estimate from the balance sheet, not a forecast of failure. The debt, cash-flow and return sections above carry the balance-sheet evidence this page does hold, and each of them states its own reporting date.
The safety line in one sentence: the Z-score is not available for this stock, so we say so rather than invent one.
| Company | P/E | Mkt cap | Revenue | EPS | ROCE | Stage |
|---|---|---|---|---|---|---|
| Cohance Lifesciences Ltd this page | 80.9× | ₹15,957 Cr | Deteriorating | |||
| Divis Laboratories Ltd | 73.4× | ₹1.9L Cr | Mixed | |||
| Laurus Labs Ltd | 79.1× | ₹86,505 Cr | Mixed | |||
| Anthem Biosciences Ltd | 73.1× | ₹43,360 Cr | No read | |||
| Gland Pharma Ltd | 37.6× | ₹39,257 Cr | Improving | |||
| Acutaas Chemicals Ltd | 75.2× | ₹26,785 Cr | Improving | |||
| Acutaas Chemicals Ltd | 69.1× | ₹26,686 Cr | Mixed | |||
| Sai Life Sciences Ltd | 73.8× | ₹26,174 Cr | No read | |||
| Piramal Pharma Ltd | — | ₹24,133 Cr | No read | |||
| Neuland Laboratories Ltd | 65.9× | ₹23,794 Cr | Turning around | |||
| Granules India Ltd | 31.8× | ₹20,655 Cr | Consistent | |||
| OneSource Specialty Pharma Ltd | — | ₹18,961 Cr | No read | |||
| Syngene International Ltd | 44.9× | ₹16,708 Cr | Turning around | |||
| Syngene International Ltd | 44.1× | ₹16,415 Cr | Turning around | |||
| Jubilant Pharmova Ltd | 35.2× | ₹15,378 Cr | No read | |||
| Concord Biotech Ltd | 54.8× | ₹13,061 Cr | Deteriorating | |||
| Shilpa Medicare Ltd | 50.8× | ₹11,856 Cr | No read | |||
| Blue Jet Healthcare Ltd | 43.3× | ₹10,730 Cr | Deteriorating | |||
| Supriya Lifescience Ltd | 32.3× | ₹6,765 Cr | Consistent | |||
| IOL Chemicals & Pharmaceuticals Ltd | 30.0× | ₹4,380 Cr | Improving | |||
| SMS Pharmaceuticals Ltd | 35.0× | ₹3,569 Cr | Mixed | |||
| Morepen Laboratories Ltd | 39.6× | ₹2,948 Cr | Mixed | |||
| Dishman Carbogen Amcis Ltd | 29.0× | ₹2,878 Cr | No read | |||
| Hikal Ltd | 73.8× | ₹2,681 Cr | Deteriorating | |||
| Solara Active Pharma Sciences Ltd | 551.0× | ₹2,351 Cr | No read | |||
| Windlas Biotech Ltd | 26.6× | ₹1,770 Cr | Mixed |
Frequently asked questions
What is Cohance Lifesciences Ltd's share price today?
Cohance Lifesciences Ltd trades at ₹442, −59.2% over the past year. The company is valued at ₹15,957 Cr. The stock sits at 23% of its 52-week range of ₹280–₹980, −15.1% versus its 200-day average. On the tape, the price is in a downtrend, 56 weeks in. — as of 24 July 2026.
What were Cohance Lifesciences Ltd's latest quarterly results?
Cohance Lifesciences Ltd reported revenue of ₹619 Cr and net profit of ₹8.3 Cr for the Mar 26 quarter. Revenue fell 26.3% and profit fell 92.9% year on year. Earnings per share were ₹0.51. The operating margin was 15.9%, 11.3 pp lower than a year earlier. — as of 24 July 2026.
What is Cohance Lifesciences Ltd's revenue?
Cohance Lifesciences Ltd reported revenue of ₹619 Cr in the Mar 26 quarter, −26.3% year on year. For the full FY26 fiscal year, revenue was ₹2,269 Cr (+89.4%). Over the last 7 years revenue compounded at 29.2% a year. — as of 24 July 2026.
What is Cohance Lifesciences Ltd's profit?
Cohance Lifesciences Ltd earned ₹8.3 Cr of net profit in the Mar 26 quarter, −92.9% year on year. Full-year FY26 profit was ₹150 Cr. The operating margin ran 15.9% in the latest quarter. — as of 24 July 2026.
What is Cohance Lifesciences Ltd's market cap?
Cohance Lifesciences Ltd's market capitalisation is ₹15,957 Cr at a share price of ₹442. Market cap is the share price multiplied by shares outstanding, so it is restated whenever the price moves. — as of 24 July 2026.
What is Cohance Lifesciences Ltd's P/E ratio?
Cohance Lifesciences Ltd trades at a P/E of 80.9×, at the 86th percentile of its own 6-year range, against a long-run median of 35.4×. This is a comparison with the stock's own history, not a value call — as of 24 July 2026.
Does Cohance Lifesciences Ltd pay a dividend?
Not in its latest year — Cohance Lifesciences Ltd's dividend payout was 0% of profit in FY26. It did record a payout in 4 of its last 8 reported fiscal years, so there is a history but no current dividend. This page holds the payout ratio, not a per-share amount. — as of 24 July 2026.
Is Cohance Lifesciences Ltd overvalued?
On its own history, Cohance Lifesciences Ltd looks expensive against its own history: its P/E of 80.9× sits at the 86th percentile of its 6-year range (long-run median 35.4×). That is a percentile read against the stock's own past, not a price opinion or a direction call. — as of 24 July 2026.
Is Cohance Lifesciences Ltd growing?
Not right now — Cohance Lifesciences Ltd's latest numbers are shrinking: latest-quarter revenue −26.3% year on year, profit −92.9%, and the margin −11.3 pp at 15.9%. The 7-year compound rates are 29.2% (revenue) and 4.7% (profit). The earnings engine currently reads: deteriorating — as of 24 July 2026.
How is Cohance Lifesciences Ltd performing?
Cohance Lifesciences Ltd is in a downtrend, 56 weeks in. Its latest quarter's revenue fell 26.3% and profit fell 92.9% year on year. Against the NIFTY 500 it has been ahead on a trailing-13-week view for 2 weeks. This describes what the data did, not a rating. — as of 24 July 2026.
What stage is Cohance Lifesciences Ltd in?
Deteriorating — revenue and profit growth are shrinking (revenue growth −26.3% latest (single-quarter readings) against +100.0% at its 12-quarter best), ROCE slipping at 8.0%. The read comes from the last 12 quarters of growth (revenue growth −26.3% latest, profit growth −92.9% latest) plus the ROCE curve, classified by deterministic rules — a trajectory read, not a buy or sell call — as of 24 July 2026.
Is Cohance Lifesciences Ltd in an uptrend?
No — the price is in a downtrend (week 56 of stage 4), trading −15.1% versus its 200-day average and at 23% of its 52-week range. Price stages cycle base → advance → top → decline, and the stage names where this stock sits in that cycle — as of 24 July 2026.
Is Cohance Lifesciences Ltd beating the market?
On recent form, yes — Cohance Lifesciences Ltd has been ahead of the NIFTY 500 on a trailing-13-week view for 2 straight weeks, the same metric the week-by-week ribbon on this page draws. Separately, on the cumulative view: over the last 6.3 years the stock moved +203% against the NIFTY 500's +233% — behind the index over the full window. — as of 24 July 2026.
Will Cohance Lifesciences Ltd's share price go up?
This page publishes no price forecast for Cohance Lifesciences Ltd. What it measures instead: the share price is ₹442, the price is in a downtrend 56 weeks in. Its P/E of 80.9× sits at the 86th percentile of its own 6-year range. — as of 24 July 2026.
Who owns Cohance Lifesciences Ltd?
Promoters hold 57.5% of Cohance Lifesciences Ltd, foreign institutions 6.5%, domestic institutions 20.1% and the public 15.9% (latest quarter). The biggest move on the register over the last two years: Promoters added 7.4 points over 8 quarters. — as of 24 July 2026.
Does Cohance Lifesciences Ltd have too much debt?
No — Cohance Lifesciences Ltd's debt-to-equity is 0.10, and operating profit covers the interest bill 12×. FY26 borrowings were ₹400 Cr against equity of ₹3,911 Cr. The returns on this page are earned, not borrowed — as of 24 July 2026.
What is Cohance Lifesciences Ltd's capex?
Cohance Lifesciences Ltd spent ₹3,037 Cr on capital expenditure over the last 3 fiscal years, a figure derived from the change in fixed assets plus depreciation. In FY26 alone that was ₹1,764 Cr, with ₹173 Cr in capital work-in-progress — capacity paid for but not yet earning. — as of 24 July 2026.
What is Cohance Lifesciences Ltd's cash flow?
Cohance Lifesciences Ltd generated ₹368 Cr of operating cash flow in FY26 and ₹−1,396 Cr of free cash flow after ₹1,764 Cr of capital spending. Reported profit that year was ₹150 Cr, so operating cash ran ahead of profit. Cash-flow resolution for India is annual. — as of 24 July 2026.
Is Cohance Lifesciences Ltd's profit real cash?
Yes — over the last 3 fiscal years, 142% of Cohance Lifesciences Ltd's reported profit arrived as operating cash. In FY26, operating cash was ₹368 Cr against reported profit of ₹150 Cr. The cash then goes mostly into building capacity. Cash-flow resolution is annual — as of 24 July 2026.
Where is Cohance Lifesciences Ltd in its business cycle?
Cohance Lifesciences Ltd's FY26 operating margin was 19.0%, against a 8-year band of 19.0%–46.0%: the low end of its own band, which is where recoveries start when they come. The latest quarter ran 15.9%. Profitability versus a company's own long band is the cleanest cycle clock this page holds — as of 24 July 2026.
What could break the Cohance Lifesciences Ltd story?
The sharpest disagreement: Promoters moved +7.4 points over 8 quarters while the operating story went the other way — someone close to the numbers is not convinced. Mechanically, two Friday closes in a row below the 200-day average would end the price trend — that is the exit rule this page tracks — as of 24 July 2026.
Is Cohance Lifesciences Ltd a stock worth studying right now?
This is not investment advice. The machine read: Cohance Lifesciences Ltd's three tracks disagree. Price, valuation and the earnings engine each tell a different story — the next quarter or two settles it. The sharpest open question: whether the register turns back in the story’s favour. Every number on this page is drawn deterministically from the raw series, with no forecasts and no price opinions — as of 24 July 2026.